Pharma Pulse 11/15/24: Practical Gains for Pharma AI Use, Small-Molecules Are More Cost Effective & more
The latest news for pharma industry insiders.
The Leap Forward: Practical Gains for Pharma AI Use
Exploring those areas and functions where the application of generative artificial intelligence—through use cases borne out in practice—are demonstrating tangible value and driving life sciences innovation to new heights.
Small-Molecules Are More Cost Effective Than Biologics, Tufts Researchers Find
Their results argue for a change to parity between small-molecule agents and biologics when it comes to Inflation Reduction Act price negotiation timelines, the researchers say.
Merck Snags Chinese Cancer Drug For Up to $3.3 Billion
Merck & Co. licensed an experimental cancer antibody from a closely held Chinese company in a deal worth $588 million upfront, plus as much as $2.7 billion in milestone payments.
Olfactive Biosolutions, the leader in harnessing food molecules for the treatment of chronic diseases, has begun production of its Protenx™ GLP-1/GIP Weight Loss patented weight loss and blood sugar reduction formulation under its U.S. patent US 12,102,664.
"While noncompliant trading partners must prioritize necessary changes, the exemption also presents a valuable opportunity for all members of the supply chain to optimize processes and procedures. It should not be seen as a reason to delay implementing the final requirements of the law.," Sample says.
Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs
